What is the share price of Gennex Laboratories Ltd (GENNEX) today?
The share price of GENNEX as on 18th September 2026 is ₹10.32. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Gennex Laboratories Ltd (GENNEX) share?
The past returns of Gennex Laboratories Ltd (GENNEX) share are- Past 1 week: -7.94%
- Past 1 month: -15.13%
- Past 3 months: -3.48%
- Past 6 months: 8.22%
- Past 1 year: -20.57%
- Past 3 years: 31.67%
- Past 5 years: 51.25%
What are the peers or stocks similar to Gennex Laboratories Ltd (GENNEX)?
The peers or stocks similar to Gennex Laboratories Ltd (GENNEX) include:What is the market cap of Gennex Laboratories Ltd (GENNEX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gennex Laboratories Ltd (GENNEX) is ₹249.51 Cr as of 18th September 2026.What is the 52 week high and low of Gennex Laboratories Ltd (GENNEX) share?
The 52-week high of Gennex Laboratories Ltd (GENNEX) is ₹17.25 and the 52-week low is ₹7.05.What is the PE and PB ratio of Gennex Laboratories Ltd (GENNEX) stock?
The P/E (price-to-earnings) ratio of Gennex Laboratories Ltd (GENNEX) is 13.52. The P/B (price-to-book) ratio is 1.28.Which sector does Gennex Laboratories Ltd (GENNEX) belong to?
Gennex Laboratories Ltd (GENNEX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Gennex Laboratories Ltd (GENNEX) shares?
You can directly buy Gennex Laboratories Ltd (GENNEX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Gennex Laboratories Ltd
GENNEX Share Price
BSE₹10.321.34% (-0.14)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
GENNEX Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
GENNEX Performance & Key Metrics
GENNEX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.63 | 1.28 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.20 | 5.92 | 0.48% |
GENNEX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GENNEX Company Profile
Gennex Laboratories Limited is engaged in manufacturing of bulk drugs, intermediates and biotech products. Its product portfolio is spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal.
SUNPHARMA
PE Ratio
38.40
38.40
1Y Return
11.45%
11.45%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
85.10
85.10
1Y Return
35.67%
35.67%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
22.96
22.96
1Y Return
10.70%
10.70%
Buy Reco %
55.56
55.56
CIPLA
PE Ratio
29.04
29.04
1Y Return
11.64%
11.64%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
118.79
118.79
1Y Return
111.64%
111.64%
Buy Reco %
58.33
58.33
GENNEX Forecast
GENNEX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
GENNEX
GENNEX
Income
Balance Sheet
Cash Flow
Quarterly Normal View
GENNEX Income Statement
GENNEX Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 35.52 | 30.79 | 33.38 | 40.01 | 44.16 | 36.45 | 39.30 | 42.96 | 62.27 | 41.85 | ||||||||||
Operating & Other expenses | 29.26 | 24.09 | 25.93 | 32.85 | 38.46 | 29.11 | 31.75 | 34.68 | 55.37 | 35.46 | ||||||||||
EBITDA | 6.26 | 6.70 | 7.45 | 7.16 | 5.70 | 7.34 | 7.55 | 8.28 | 6.90 | 6.39 | ||||||||||
| Depreciation/Amortization | 0.23 | 0.45 | 1.11 | 0.50 | 0.54 | 0.50 | 0.47 | 0.52 | 1.16 | 0.90 | ||||||||||
| PBIT | 6.03 | 6.25 | 6.34 | 6.66 | 5.16 | 6.84 | 7.08 | 7.76 | 5.74 | 5.49 | ||||||||||
| Interest & Other Items | 0.73 | 0.73 | 0.22 | 0.84 | 1.20 | 0.98 | 1.03 | 1.11 | 1.08 | 0.57 | ||||||||||
| PBT | 5.30 | 5.52 | 6.12 | 5.82 | 3.96 | 5.86 | 6.05 | 6.65 | 4.66 | 4.92 | ||||||||||
| Taxes & Other Items | 0.81 | 1.09 | 1.30 | 1.17 | 1.63 | 1.27 | 1.03 | 1.41 | 0.93 | 0.60 | ||||||||||
| Net Income | 4.49 | 4.43 | 4.82 | 4.65 | 2.33 | 4.59 | 5.02 | 5.24 | 3.73 | 4.32 | ||||||||||
| EPS | 0.16 | 0.19 | 0.21 | 0.22 | 0.14 | 0.22 | 0.21 | 0.22 | 0.16 | 0.19 |
GENNEX Company Updates
GENNEX Stock Peers
GENNEX Past Performance & Peer Comparison
GENNEX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gennex Laboratories Ltd | 13.52 | 1.28 | — |
| Sun Pharmaceutical Industries Ltd | 38.40 | 5.26 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.10 | 10.47 | 0.70% |
| Zydus Lifesciences Ltd | 22.96 | 3.91 | 0.09% |
GENNEX Stock Price Comparison
Compare GENNEX with any stock or ETFCompare GENNEX with any stock or ETF
GENNEX
GENNEX Holdings
GENNEX Shareholdings
GENNEX Promoter Holdings Trend
GENNEX Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GENNEX Institutional Holdings Trend
GENNEX Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GENNEX Shareholding Pattern
GENNEX Shareholding Pattern
GENNEX Shareholding History
GENNEX Shareholding History
Foreign Institutions
smallcases containing GENNEX stock
smallcases containing GENNEX stock
Looks like this stock is not in any smallcase yet.
GENNEX Events
GENNEX Events
GENNEX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GENNEX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
GENNEX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GENNEX has not given any dividends in last 5 years
GENNEX Dividends
GENNEX Dividends
Hmm, looks like data is unavailable here. Please come back after some timeGENNEX Stock News & Opinions
GENNEX Stock News & Opinions
Articles & Videos
Earnings
Earnings
Gennex Laboratories Ltd consolidated sales down 34.65% on year in Q2FY2026, net profit saw a marginal increase of 4.71%Gennex Laboratories Ltd share price rallied 13.30% to Rs 10.82 after the company's net profit inched up 4.71% to Rs 4.67 crore, while revenue from operations plunged by 34.65% to Rs 39.84 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.59%. It has marginally improved by 0.05% over last one week and moving up by 10.53% in last one month while the market capitalization of Gennex Laboratories Ltd has significantly gained 20.89% and 13.65% in the same period respectively. Profit before tax (PBT) of Gennex Laboratories Ltd stood at Rs 4.92 crore in Q2 FY26, nosediving by 16.18% year-on-year, and easing 5.35% quarter-on-quarter. EBITDA came in at Rs 2 crore, tumbling by 15.05% YoY and tanking 48.14% sequentially. Total expenses slumped by 35.34% to Rs 36.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 29.67 crore, slumping by 46.34% YoY, while employee benefits expense was at Rs 1.98 crore, soaring 69.23% YoY. For the TTM ended FY26, revenue from operations soared by 59.04% to Rs 137.9 crore, while net profit saw a strong growth of 37.48% to Rs 18.12 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 2056% to Rs 6.29 crore, and PBT jumped 29.78% to Rs 21.4 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 10.8 crore in FY26, as against Rs 46.69 crore in FY25. Gennex Laboratories Ltd crashed 23.29% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.
1 month agoCapital Market - Live
Earnings
Earnings
Gennex Laboratories consolidated net profit rises 61.21% in the March 2026 quarterNet profit of Gennex Laboratories rose 61.21% to Rs 3.74 crore in the quarter ended March 2026 as against Rs 2.32 crore during the previous quarter ended March 2025. Sales rose 51.15% to Rs 60.96 crore in the quarter ended March 2026 as against Rs 40.33 crore during the previous quarter ended March 2025. For the full year,net profit rose 14.52% to Rs 18.46 crore in the year ended March 2026 as against Rs 16.12 crore during the previous year ended March 2025. Sales rose 25.26% to Rs 172.74 crore in the year ended March 2026 as against Rs 137.90 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales60.9640.33 51 172.74137.90 25 OPM %9.655.01 -12.9819.69 - PBDT6.134.65 32 26.4923.54 13 PBT4.974.10 21 23.8421.55 11 NP3.742.32 61 18.4616.12 15 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories to discuss resultsGennex Laboratories will hold a meeting of the Board of Directors of the Company on 30 May 2026.
4 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories EGM scheduledGennex Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 12 May 2026.
5 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories to convene board meetingGennex Laboratories will hold a meeting of the Board of Directors of the Company on 16 April 2026.
5 months agoCapital Market - Live
Earnings
Earnings
Gennex Laboratories consolidated net profit rises 12.93% in the December 2025 quarterNet profit of Gennex Laboratories rose 12.93% to Rs 5.24 crore in the quarter ended December 2025 as against Rs 4.64 crore during the previous quarter ended December 2024. Sales rose 7.05% to Rs 40.37 crore in the quarter ended December 2025 as against Rs 37.71 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales40.3737.71 7 OPM %21.2318.96 - PBDT7.466.31 18 PBT6.945.82 19 NP5.244.64 13 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories to table resultsGennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Gennex Laboratories consolidated net profit rises 4.14% in the September 2025 quarterNet profit of Gennex Laboratories rose 4.14% to Rs 5.03 crore in the quarter ended September 2025 as against Rs 4.83 crore during the previous quarter ended September 2024. Sales rose 18.03% to Rs 37.24 crore in the quarter ended September 2025 as against Rs 31.55 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales37.2431.55 18 OPM %14.7723.61 - PBDT6.537.24 -10 PBT6.066.12 -1 NP5.034.83 4 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories to discuss resultsGennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Gennex Laboratories to hold AGMGennex Laboratories announced that the 40th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 24.64%, vs industry avg of 11.76%
Over the last 5 years, market share increased from 0.02% to 0.04%
Over the last 5 years, net income has grown at a yearly rate of 35.51%, vs industry avg of 10.45%